An Extension Study to Evaluate the Safety and Efficacy of an Anti-CD19 CAR-T Product in Patients with B-cell Lymphoproliferative Disorders
Not yet recruitingOBSERVATIONAL
Enrollment
60
Participants
Timeline
Start Date
January 9, 2025
Primary Completion Date
June 30, 2026
Study Completion Date
September 30, 2026
Conditions
Non-Hodgkin Lymphoma, B-cellAcute Lymphoblastic Leukemia ALL
Trial Locations (1)
125167
National Medical Research Center for Hematology, Moscow
All Listed Sponsors
lead
National Research Center for Hematology, Russia
NETWORK
NCT06721598 - An Extension Study to Evaluate the Safety and Efficacy of an Anti-CD19 CAR-T Product in Patients with B-cell Lymphoproliferative Disorders | Biotech Hunter | Biotech Hunter